[Testosterone replacement therapy for hypogonadism in men with prostate cancer]. 2017

Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
fullejensen@gmail.com.

Hypogonadism and prostate cancer (PCa) often coincide with increasing age. Recent reviews have found no evidence to suggest an increased risk of developing PCa with testosterone replacement therapy (TRT). The same lack of PCa risk is found in studies looking at men receiving TRT after radical prostatectomy for PCa. Reports on TRT in men on active surveillance are very few. In summary, current evidence does not support an association between TRT and an increased risk of PCa. Nevertheless, sufficiently powered trials with longer follow-up are warranted before making final conclusions.

UI MeSH Term Description Entries
D007006 Hypogonadism Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism). Hypergonadotropic Hypogonadism,Hypogonadism, Isolated Hypogonadotropic,Hypogonadotropic Hypogonadism,Hypogonadism, Hypergonadotropic,Hypogonadism, Hypogonadotropic
D008297 Male Males
D011468 Prostatectomy Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE). Prostatectomy, Retropubic,Prostatectomy, Suprapubic,Prostatectomies,Prostatectomies, Retropubic,Prostatectomies, Suprapubic,Retropubic Prostatectomies,Retropubic Prostatectomy,Suprapubic Prostatectomies,Suprapubic Prostatectomy
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D013739 Testosterone A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. 17-beta-Hydroxy-4-Androsten-3-one,17-beta-Hydroxy-8 alpha-4-Androsten-3-one,8-Isotestosterone,AndroGel,Androderm,Andropatch,Androtop,Histerone,Sterotate,Sustanon,Testim,Testoderm,Testolin,Testopel,Testosterone Sulfate,17 beta Hydroxy 4 Androsten 3 one,17 beta Hydroxy 8 alpha 4 Androsten 3 one,8 Isotestosterone
D017410 Practice Guidelines as Topic Works about directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. Clinical Guidelines as Topic,Best Practices,Best Practice
D020249 Hormone Replacement Therapy Therapeutic use of hormones to alleviate the effects of hormone deficiency. Replacement Therapy, Hormone,Therapy, Hormone Replacement,Hormone Replacement Therapies,Replacement Therapies, Hormone,Therapies, Hormone Replacement

Related Publications

Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
January 2014, Aktuelle Urologie,
Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
September 2019, American journal of epidemiology,
Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
April 2024, JAMA internal medicine,
Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
January 2015, International braz j urol : official journal of the Brazilian Society of Urology,
Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
December 2020, International journal of molecular sciences,
Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
December 2023, JAMA network open,
Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
January 2022, Drugs in context,
Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
March 2014, Endocrinology and metabolism (Seoul, Korea),
Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
February 2007, Cancer,
Christian F S Jensen, and Mikkel Fode, and Peter Østergren, and Jens Sønksen
September 2005, BJU international,
Copied contents to your clipboard!